Last reviewed · How we verify

Levobupivacaine 0,5%

ASST Gaetano Pini-CTO · FDA-approved active Small molecule

Levobupivacaine 0,5% is a Local anesthetic (amide) Small molecule drug developed by ASST Gaetano Pini-CTO. It is currently FDA-approved for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

Levobupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

Levobupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic nameLevobupivacaine 0,5%
SponsorASST Gaetano Pini-CTO
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

As the S-enantiomer of bupivacaine, levobupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve fibers. This prevents depolarization and transmission of nerve impulses, resulting in local anesthesia. Levobupivacaine has a lower cardiotoxicity profile compared to racemic bupivacaine due to reduced myocardial sodium channel blockade.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levobupivacaine 0,5%

What is Levobupivacaine 0,5%?

Levobupivacaine 0,5% is a Local anesthetic (amide) drug developed by ASST Gaetano Pini-CTO, indicated for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

How does Levobupivacaine 0,5% work?

Levobupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

What is Levobupivacaine 0,5% used for?

Levobupivacaine 0,5% is indicated for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks, Epidural anesthesia.

Who makes Levobupivacaine 0,5%?

Levobupivacaine 0,5% is developed and marketed by ASST Gaetano Pini-CTO (see full ASST Gaetano Pini-CTO pipeline at /company/asst-gaetano-pini-cto).

What drug class is Levobupivacaine 0,5% in?

Levobupivacaine 0,5% belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is Levobupivacaine 0,5% in?

Levobupivacaine 0,5% is FDA-approved (marketed).

What are the side effects of Levobupivacaine 0,5%?

Common side effects of Levobupivacaine 0,5% include Hypotension, Bradycardia, Nausea, Headache, Dizziness, Systemic toxicity (CNS and cardiac effects at high doses).

What does Levobupivacaine 0,5% target?

Levobupivacaine 0,5% targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related